Appointment of new CEO

The Board of Rarity Bioscience is pleased to announce the appointment of Linus Bosaeus as the new Chief Executive Officer of Rarity Bioscience with effect from 6th of September 2021.

Linus has a background is physics and has been working in the life science industry for the past ten years. In prior positions, his role has been development and commercialization of medical device and technology, including fundraising and management of operations.

“We are pleased to see that Linus Bosaeus has accepted the position as CEO of Rarity Bioscience and we are certain that he will add relevant commercial and medical device experience and balance to the founding team. His prior experiences from startups will also support the growth and expansion of the company”, says Chair of the Board Mikael Smedeby,

“I’m very excited to join Rarity Bioscience and it is impossible not be impressed by the achievements by the company so far. The research by Lei Chen is quite unique and the track record by Ulf Landegren when it comes to commercializing research speaks for itself.“ – says Linus BosaeusThe board also extends its deepest gratitude to Per Matsson who has been interim CEO during the company formation, and who now becomes deputy chairman next to Mikael Smedeby.

Share this article

Recommended articles

Rarity Bioscience at the CYTO 2024 Conference

Rarity Bioscience’s Linus Bosaeus and Lei Chen was at the CYTO 2024 Conference in Edinburgh, to present the study Ultra-sensitive Molecular MRD on Flow Cytometer using superRCA Mutation Assay, showcasing our new ultra-sensitive mutation detection technology superRCA.

Read more »

Rarity Bioscience at the Nordic Precision Medicine Forum

Rarity Bioscience was at the Nordic Precision Medicine Forum, presenting an engaging study that highlights the latest advancements in precision oncology: ”Ultra-sensitive Monitoring of Minimal Residual Disease (MRD) for Cancer Patients, using superRCA Mutation Assays with Flow Cytometry Readout”

Read more »